Venus Remedies Hits Lower Circuit Amid Heavy Selling Pressure

Intraday Price Movement and Circuit Trigger

On the trading day, Venus Remedies recorded a high price of ₹823.00 and a low of ₹784.15, with the last traded price settling at the day’s low of ₹784.15. This represented a maximum daily loss of 5.0%, triggering the lower circuit mechanism designed to curb excessive volatility. The price band for the stock was set at ₹5, limiting the permissible price movement within the session. The weighted average price indicated that the majority of traded volume clustered near the lower end of the price range, underscoring the dominance of sellers throughout the day.

Volume and Turnover Analysis

Trading volumes for Venus Remedies stood at approximately 32,645 shares (0.32645 lakhs), generating a turnover of ₹2.62 crore. While the stock is classified as liquid enough to support trade sizes up to ₹0.09 crore based on 2% of its five-day average traded value, the current session’s volume was relatively modest. Notably, delivery volumes on 12 Dec showed a decline of nearly 32% compared to the five-day average, suggesting a reduction in investor participation and possibly contributing to the stock’s downward momentum.

Comparative Performance and Market Context

Venus Remedies’ one-day return of -5.00% contrasted sharply with the Pharmaceuticals & Biotechnology sector’s marginal decline of -0.25% and the Sensex’s near-flat movement at -0.06%. Over the past two days, the stock has recorded consecutive losses amounting to a cumulative return of -5.91%, indicating sustained selling pressure. Despite this short-term weakness, the stock remains priced above its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, reflecting a longer-term upward trend that has yet to be disrupted by the recent sell-off.

Investor Sentiment and Supply-Demand Dynamics

The sharp fall and circuit hit suggest a scenario of panic selling, where investors rushed to exit positions amid negative sentiment. The unfilled supply at lower price points indicates that sellers were unable to find sufficient buyers, leading to the imposition of the lower circuit to prevent further freefall. This phenomenon often reflects uncertainty or adverse news flow impacting the stock, although no specific announcements were noted on the day.

Market Capitalisation and Sector Positioning

Venus Remedies is classified as a micro-cap company with a market capitalisation of approximately ₹1,057 crore. Operating within the Pharmaceuticals & Biotechnology industry, the company’s stock is subject to sector-specific factors such as regulatory developments, research and development outcomes, and broader healthcare trends. The sector’s relatively stable performance on the day contrasts with the stock’s sharp decline, highlighting company-specific pressures rather than sector-wide weakness.

Technical Indicators and Moving Averages

Despite the recent downturn, Venus Remedies continues to trade above its key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages. This technical positioning suggests that the stock’s longer-term momentum remains intact, although the immediate challenge will be to stabilise prices and absorb the selling pressure. Investors and traders will be closely monitoring volume patterns and price action in the coming sessions to gauge whether the lower circuit event marks a temporary pause or the start of a more extended correction.

Outlook and Investor Considerations

For investors, the recent price action in Venus Remedies highlights the importance of monitoring liquidity and volume trends alongside price movements. The stock’s ability to maintain levels above its moving averages may offer some reassurance, but the immediate concern remains the heavy selling pressure and the psychological impact of the lower circuit hit. Market participants should consider broader sector dynamics, company-specific developments, and overall market conditions when assessing the stock’s near-term prospects.

Conclusion

Venus Remedies’ experience on 15 Dec 2025 serves as a reminder of the volatility that can affect micro-cap stocks within the Pharmaceuticals & Biotechnology sector. The lower circuit event underscores the presence of unfilled supply and panic selling, which may prompt a period of consolidation or further volatility. Investors are advised to stay informed through comprehensive research and maintain a balanced perspective on the stock’s valuation and technical signals.

Only ₹14,999 - Get MojoOne + Stock of the Week for 2 Years PLUS 6 Months FREE Claim 83% OFF →